Pre-results note
Ticks a lot of boxes in an uncertain environment - Q1 preview
Kristofer Liljeberg
Elvin Rolder
2026-03-31
19:18 CEST
We expect another quarter of solid progress from Carasent with 13% organic revenue growth, slightly affected by the dilutive effects that the German business has on group growth until Webdoc for Germany starts to contribute to growth in the region. We leave our estimates more or less unchanged ahead of the Q1 report and reiterate our fair value range of SEK33–45 per share.
We expect another quarter of solid progress. We expect continued solid momentum from Carasent in Q1, with continued organic growth in the teens, and robust margin expansion Y/Y. The recently implemented Volvat deal in Norway and Medtanken in Sweden’s Västra Götaland region support the revenue growth profile. However, the lack of growth in the German business at present will dilute the continued strength in the Nordic operations, we believe. We expect revenue in Q1 of SEK95m, corresponding to 13% organic growth Y/Y. In terms of profitability, we expect continued Y/Y improvements as cost growth Y/Y remains limited, and we pencil in an adj. EBITDAC margin of 12.2% (5.6%), up ~6.5%-points Y/Y. We leave our estimates virtually unchanged ahead of the Q1 report.
A story that ticks a lot of boxes. We believe Carasent’s story ticks a lot of boxes in the current uncertain environment as most of its revenue is recurring (+90%) and its customers primarily are private primary and specialty care clinics, providing predictable and highly sticky revenue with very low churn. With the Millennium situation in Västra Götaland finally resolved, with the region opting for a modular solution, the SEK15m–20m churn risk that has been somewhat of an overhang over the share has been removed, and the propensity for private primary care clinics in the region to change EHR should increase as the uncertainties with Millennium subside, we believe. Given the roll-out of Webdoc in Germany, coupled with the development in Stockholm, we believe the organic growth potential for Carasent in the coming years looks highly promising. As our estimates are more or less unchanged, we leave our fair value range at SEK33–45/share.